首药控股-U
(688197)
| 流通市值：22.73亿 | | | 总市值：52.81亿 |
| 流通股本：6400.49万 | | | 总股本：1.49亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 28,000,000 | 28,000,000 | 8,667,574.64 | 2,000,000 |
| 营业收入 | 28,000,000 | 28,000,000 | 8,667,574.64 | 2,000,000 |
| 二、营业总成本 | 95,292,699 | 45,718,695.9 | 216,068,880.01 | 170,147,424.42 |
| 营业成本 | - | 0 | 266,099.45 | - |
| 税金及附加 | 62,811.15 | 27,095.55 | 46,424.03 | 33,810.32 |
| 销售费用 | 2,387,867.6 | 316,930.81 | - | - |
| 管理费用 | 11,980,137.36 | 4,866,513.32 | 19,582,965.21 | 15,339,916.57 |
| 研发费用 | 80,832,679.39 | 40,495,156.42 | 196,700,247.71 | 155,269,560.36 |
| 财务费用 | 29,203.5 | 12,999.8 | -526,856.39 | -495,862.83 |
| 其中:利息费用 | 180,014.39 | 76,064.89 | 133,135.3 | 115,459.69 |
| 其中:利息收入 | 153,850.63 | 64,571.65 | 664,191 | 614,430.4 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,864,014.17 | 1,247,280.85 | 7,100,677.75 | 6,047,173.18 |
| 加:投资收益 | 4,216,145.97 | 1,537,709.29 | 9,342,856.12 | 6,756,262.57 |
| 信用减值损失(新) | 18,162.06 | -250,657.1 | -19,018.23 | -795,748.14 |
| 其他收益 | 100,628.4 | 93,608.4 | 61,501,708.17 | 981,771.57 |
| 四、营业利润 | -61,093,748.4 | -15,090,754.46 | -129,475,081.56 | -155,157,965.24 |
| 加:营业外收入 | 34,341 | - | 650,008.85 | 400,008.85 |
| 减:营业外支出 | - | - | 9,170.7 | 9,170.7 |
| 五、利润总额 | -61,059,407.4 | -15,090,754.46 | -128,834,243.41 | -154,767,127.09 |
| 六、净利润 | -61,059,407.4 | -15,090,754.46 | -128,834,243.41 | -154,767,127.09 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -61,059,407.4 | -15,090,754.46 | -128,834,243.41 | -154,767,127.09 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -61,059,407.4 | -15,090,754.46 | -128,834,243.41 | -154,767,127.09 |
| 扣除非经常损益后的净利润 | -67,183,121.52 | -17,877,937.58 | -207,318,892.2 | -168,841,741.16 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.41 | -0.1 | -0.87 | -1.04 |
| (二)稀释每股收益 | -0.41 | -0.1 | -0.87 | -1.04 |
| 九、综合收益总额 | -61,059,407.4 | -15,090,754.46 | -128,834,243.41 | -154,767,127.09 |
| 归属于母公司股东的综合收益总额 | -61,059,407.4 | -15,090,754.46 | -128,834,243.41 | -154,767,127.09 |
| 公告日期 | 2026-08-29 | 2026-04-18 | 2026-04-18 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |